Spanish Health Ministry to Fund Generic Version of "Champix"

Regulations by 2FIRSTS.ai

May.30.2024

Spanish Health Ministry to Fund Generic Version of "Champix"

Spain's Health Ministry to fund generic version of "Champix" from June, after original version pulled due to impurities.

According to El Mundo on May 29th, the Spanish Ministry of Health will start funding generic versions of "Champix" from June, a drug that was previously removed from the market due to impurities found in the production process of its main component, Varenicline.

Susana Verdejo, director of the Tobacco Prevention and Control Department at the Spanish Ministry of Health, revealed during a World No Tobacco Day meeting on Wednesday (May 29) that the active ingredient varenicline in the pharmaceutical giant Pfizer's drug "Champix" was ordered to be removed from shelves in 2021 by the Spanish Agency of Medicines and Medical Devices (AEMPS) due to the presence of carcinogenic nitrosamine impurities above permitted levels during the manufacturing process. It is expected that in June, the version of the drug produced by the designated manufacturer Normon will be available for sale in Spanish pharmacies.

In Spain, two smoking cessation medications, "Todacitán" and "Recigarum," have received funding. Therefore, there are currently three smoking cessation medications available in Spain.

References:

[1] Sanidad financiará vareniclina, el genérico de 'Champix', como tratamiento para dejar de fumar a partir de junio

Also Read:

[1] British Tourists Face £1,700 Fine for E-Cigarettes in Spain

[2] Spanish Tobacco Prevention Committee Urges Generic Packaging for Tobacco Products

[3] Spanish National Smoking Prevention Plan to be Implemented by Year End

[4] Spain Approves New Smoking Ban Plan with Increased Taxes

[5] Canary Islands Considering Comprehensive Smoking Ban Legislation for Public Health

[6] UK Approves Sale of Promising Smoking Cessation Medication, Cytisine

#Europe #Traditional tobacco #Spain #Regulation

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Bangladesh High Court Questions Legality of BEZA’s Approval for Philip Morris Nicotine Pouch Factory

The High Court in Bangladesh has asked government bodies to explain why the approval granted to Philip Morris to establish a nicotine pouch factory should not be deemed illegal. Petitioners argue the decision contradicts existing policies and a 2016 Appellate Division ruling that restricts new tobacco-related enterprises. Authorities have ten days to respond.

Nov.20 by 2FIRSTS.ai

California DOJ Outlines Next Steps for Unflavored Tobacco List; Enforcement to Target “Obviously Flavored” Products

The California DOJ issued Information Bulletin No. 2025-DLE-17 on November 10, 2025, providing an update on the state’s flavored tobacco enforcement. The Attorney General’s office is set to launch the Unflavored Tobacco List (UTL) by December 31, 2025, identifying tobacco products without characterizing flavors that may legally be sold in California. Enforcement will continue to focus on “obviously flavored” products, while unregistered products remain subject to seizure and penalties.

Nov.17 by 2FIRSTS.ai

Cambodia Enforces Full Ban on E-Cigarettes and Shisha to Protect Youth

Cambodian Prime Minister Hun Manet signs order to strengthen enforcement of e-cigarette and shisha bans, citing health risks and youth usage.

Oct.23 by 2FIRSTS.ai

Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%

Imperial Brands reported FY25 NGP net revenue of £368 million, up 13.7% at constant currency. Growth in the Americas accelerated sharply, with NGP revenue up 69.8%, driven by the expansion of the modern oral brand Zone. Europe delivered 8.8% growth, supported by blu’s double-digit vapour share across key markets. Adjusted NGP operating losses narrowed to £76 million, putting the category closer to breakeven.